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Abstract
Background: Exercise interventions to prevent dementia and delay cognitive decline have gained considerable
attention in recent years. Human and animal studies have demonstrated that regular physical activity targets brain
function by increasing cognitive reserve. There is also evidence of structural changes caused by exercise in preventing
or delaying the genesis of neurodegeneration. Although initial studies indicate enhanced cognitive performance in
patients with mild cognitive impairment (MCI) following an exercise intervention, little is known about the effect of an
extensive, controlled and regular exercise regimen on the neuropathology of patients with MCI. This study aims to
determine the effects of an extensive exercise programme on the progression of MCI.
Methods/design: This randomised controlled clinical intervention study will take place across three European sites.
Seventy-five previously sedentary patients with a clinical diagnosis of MCI will be recruited at each site. Participants
will be randomised to one of three groups. One group will receive a standardised 1-year extensive aerobic exercise
intervention (3 units of 45 min/week). The second group will complete stretching and toning (non-aerobic) exercise
(3 units of 45 min/week) and the third group will act as the control group. Change in all outcomes will be measured
at baseline (T0), after six months (T1) and after 12 months (T2). The primary outcome, cognitive performance, will be
determined by a neuropsychological test battery (CogState battery, Trail Making Test and Verbal fluency). Secondary
outcomes include Montreal Cognitive Assessment (MoCA), cardiovascular fitness, physical activity, structural changes
of the brain, quality of life measures and measures of frailty. Furthermore, outcome variables will be related to genetic
variations on genes related to neurogenesis and epigenetic changes in these genes caused by the exercise
intervention programme.
Discussion: The results will add new insights into the prevailing notion that exercise may slow the rate of
cognitive decline in MCI.
Trial registration: ClinicalTrials.gov NCT02913053
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Background
With an advancing aging population and associated rise
in dementia prevalence in developed countries, the asso-
ciated costs and disease burden have exerted significant
pressure on economic and social systems [1]. To help
ensure an aging society live enjoyable and productive
lives, research into treating or preventing conditions
such as Alzheimer’s disease (AD) and other forms of
age-related neurodegenerative diseases is an urgent pub-
lic health priority. Today, longevity-related prevalence of
neurodegenerative diseases and especially dementia,
along with the current absence of a cure are among the
top prominent societal health-related challenges ac-
knowledged by the first G8 Summit on dementia held in
London on December 11th, 2013 [2].
Published diagnostic criteria for AD in Lancet Neur-
ology diagnose Mild Cognitive Impairment (MCI) as the
preclinical or prodromal stage of AD [3]. In MCI, several
of the clinical and neuropsychologic pathologic features
are present prior to the onset of overt AD [4]. Patients
with MCI in the earliest stage of neurodegeneration
can be clinically diagnosed, and represent a patient
cohort consistently able to participate in a structured
exercise programme. Consequently, there has been an
increased research focus on both pharmacological and
non-pharmacological strategies to optimise cognitive
function and enhance ‘brain health’ in older age [5], par-
ticularly for individuals at risk of developing AD [6].
Previous cross-sectional studies have established that
moderate activity during midlife is associated with a
lower risk of having MCI in later life, with late-life par-
ticipation in moderate exercise also associated with
lower risk for MCI [7]. A meta-analysis of randomised
controlled trials (RCTs) by Heyn et al. [8] reported bene-
ficial effects of physical activity on physical fitness and
cognitive function in adults with cognitive impairment.
In recent years, a broad range of exercise intervention
studies have demonstrated cognitive benefits can be
achieved with varying exercise modalities in populations
with MCI [9–11]. Aerobic exercise has demonstrated
significant improvements in global cognitive scores with
a weak but significant effect on memory [12]. A meta-
analysis by Gates et al. [13] examining the effects of
chronic exercise training on cognitive function in
older adults with MCI found research quality was
modest, with many studies under-powered and only
8% of cognitive outcomes demonstrating statistically
significant change. A limitation across a number of
these studies is the small sample size and variation in
MCI diagnostic criteria applied. The differing exercise
approaches used across exercise intervention studies,
coupled with the wide variation in cognitive tasks uti-
lised make it difficult to summarise and synthesise
research findings [14].
There is converging evidence from animal and human
studies that regular aerobic exercise acts as a promoter
of ’brain health‘ mediating neural homeostasis and, via
neuroprotective and neurorestorative mechanisms,
thereby counteracting brain ageing. At the behavioural
level, exercise has been found to upregulate affective
states [15, 16] and to improve cognition throughout dif-
ferent age phases [17–19] and different dimensions, in-
cluding spatial/associative learning [20, 21], attentional
processing [22], and executive control [23]. While ani-
mal research has allowed the unravelling of the under-
lying neurobiological mechanisms of exercise at the
behavioural (e.g. water maze-type tests), cellular (e.g.
neurogenesis, synaptogenesis, neuroangiogenesis), and
humoral (e.g. neurotrophic factors, inflammatory cyto-
kines) levels [24, 25], so far the neurobiological and epi-
genetic effects of exercise remains poorly understood in
humans. While preliminary results indicate that aerobic
exercise inhibits the progression of AD-like neuropathol-
ogy in an animal model [26, 27], currently there is little
information about the effects of regular physical exercise
on the progression of both functional and structural
markers at the pre-dementia and early dementia stages
in humans.
The aim of this study is to compare a 12-month struc-
tured exercise programme (aerobic and stretching and
toning group) to a control group for progression of cog-
nitive decline in MCI. The stretching and toning group
will act as a non-aerobic exercise group, controlling for
the social effect of a structured group exercise programme.
This type of low-intensity exercise intervention has previ-
ously shown some positive effects on cognitive outcomes,
as it provides participants with equivalent opportunity for
social interaction [28]. Previous exercise intervention stud-
ies in MCI that have utilised non-aerobic exercise (e.g.
stretching and toning) as a control intervention have noted
some improvement in cognitive performance [8, 29] while
others have not demonstrated significant change in cogni-
tive performance [9, 10]. The comparison between aerobic
exercise, non-aerobic exercise and a control group coupled
with the 12-month intervention period, concomitant brain
scanning, genetic and epigenetic analyses is innovative and
will be a strong addition to the growing body of literature
around exercise in MCI.
Methods/design
Study aims
The primary aim of this study is to investigate the effects
a 12-month structured exercise programme (aerobic,
and stretching and toning group) compared to a control
group for the progression of cognitive decline in MCI.
The primary hypothesis of this study is that participation
in an extensive exercise programme will demonstrate a
slower rate of cognitive decline compared to the control
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group. A secondary hypothesis is that participants in the
aerobic exercise group will demonstrate a stronger posi-
tive effect of cognitive functioning than the stretching
and toning (non-aerobic) group.
The secondary aims of this study are:
1. To examine the effects of a structured exercise
programme on MoCA scores, a screening tool of
global cognition in MCI
2. To determine the effects of a structured exercise
programme on cardiovascular fitness
3. To measure the effects of a structured exercise
programme on physical activity levels
4. To investigate a mechanism of action through
epigenetic analysis and exploration of structural and
functional changes on Magnetic Resonance Imaging
(MRI) brain pre and post 12-month intervention
5. To investigate the effects of a structured exercise
programme on quality of life measures and measures
of frailty
Study design
This proof of concept will take the form of a randomised
controlled trial to be completed across three centres in
Europe; the German Sport University Cologne, Germany,
University of Nijmegen, The Netherlands and Trinity
College Dublin, Ireland. A total of 225 participants will be
randomised (n = 75 at each site) to either a yearlong super-
vised and home based aerobic exercise programme (n = 75),
an equivalent non-aerobic stretching/toning programme
(n = 75) or to the control group (n = 75). The primary out-
come will be change in cognitive performance as measured
by a neuropsychological test battery. Secondary outcomes
will include changes in MoCA scores, cardiovascular fit-
ness, physical activity, quality of life measures, measures of
frailty, epigenetic and structural changes. Change in all
outcomes will be measured at baseline (T0), after six
months (T1) and after 12 months (T2) (see Fig. 1).
Recruitment and screening
In total, 225 previously sedentary adults aged 50 years or
older who are diagnosed with MCI will be recruited via
hospital memory clinics affiliated with the three sites
and from the community. Advertising will take place
through community centres and newspaper articles. Ini-
tial screening will be completed over the telephone to
determine eligibility. Participants who meet the following
diagnostic, inclusion and exclusion criteria and success-
fully complete baseline measures including a screening
exercise test will be enrolled.
Diagnostic criteria
Participants will have a diagnosis of MCI due to AD
according to the Albert et al. [3] criteria. All enrolled
participants with MCI will be classified as having mem-
ory decline but not dementia (Clinical Dementia Rating
global score = 0.5), consistent with established MCI
classification [3, 30].
Inclusion criteria
Participants who meet the following criteria will be eligible
to participate: (1) MoCA [31] 18–26; (2) stable medical
condition for more than 6 months; (3) stable medication
for more than 3 months; (4) adequate visual and auditory
acuity to complete neuropsychological testing; (5) electro-
cardiogram without significant abnormalities that might
Fig. 1 Participant flow through study
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interfere with the study; (6) physical ability sufficient to
allow performance of endurance exercise training; (7) cap-
acity to provide written and dated informed consent form;
(8) medical clearance to undergo a symptom-limited car-
diopulmonary exercise test and extensive aerobic exercise
training.
Participants recruited from the community via news-
paper articles and community advertisement will
complete additional testing to determine MCI status. To
distinguish between amnestic and non-amnestic MCI,
agreed education adjusted cut-offs of -2 Standard Devi-
ation (SD) for low education (<10 years of education),
-1.5 SD for the middle group (10–13 years of education)
and -1 SD for the highly educated (>13 years of educa-
tion) will be taken from the delayed recall portion of an
age adjusted episodic memory test. In Nijmegen and
Dublin this will be evaluated using the Logical Memory
(story recall) subtest of the Wechsler Memory Scale
(WMS-IV) [32, 33]. In Cologne, education scores will be
examined using the Repeatable Battery for the Assess-
ment of Neuropsychological Status (RBANS) [34] Delayed
Memory Index (Score of < 85).
Exclusion criteria
Participants will be deemed ineligible if they meet any of
the following criteria: (1) diagnosis of AD or other type
of dementia; (2) history of familial early-onset dementia;
(3) enrollment in any investigational drug study; (4) his-
tory in the past 2 years of epileptic seizures (participants
with epilepsy who have been stable off medication or
seizure free for 2 years may be included); (5) any major
psychiatric disorder (a clinical diagnosis of major depres-
sive disorder, bipolar or schizophrenia); (6) past history
or MRI evidence of brain damage, including significant
trauma, stroke, hydrocephalus, mental retardation, or
serious neurological disorder; (7) carotid stent or severe
stenosis; (8) history of myocardial infarction within pre-
vious year; (9) congestive heart failure (New York Heart
Association Class II, III or IV) (10) uncontrolled hyperten-
sion or hypotension (systolic blood pressure >200 mm Hg
and/or diastolic blood pressure >110 mm Hg at rest) [35];
(11) unstable cardiac, renal, lung, liver, or other severe
chronic disease; (12) type 2 diabetes mellitus with
hypoglycemia in the last 3 months; (13) significant history
of alcoholism or drug abuse within last 10 years; (14) en-
gagement in moderate-intensity aerobic exercise training
for more than 30 min, 3 times per week, during past 2 years;
(15) history of vitamin B12 deficiency or hypothyroidism
(stable treatment for at least 3 months is allowed); (16)
serious or non-healing wound, ulcer, or bone fracture
In Cologne and Nijmegen, participants will be invited to
complete brain MRI scans. Participants with pacemakers
or other medical metal devices will not be eligible for MRI
scanning as per standard procedures.
Withdrawal of participants
The investigator can decide to withdraw a subject from
the study for urgent medical reasons. Subjects can leave
the study at any time for any reason if they wish to do
so without any consequences. All primary analyses will
be performed on an intention-to-treat basis with all ran-
domised participants included in the primary analyses.
Participants who withdraw from the study will be invited
to attend T1 and T2 assessments.
Randomisation, allocation, concealment and blinding
Following baseline assessment, participants will be ran-
domised to one of three arms using a centrally con-
trolled computer generated randomisation list (for each
country) generated by an independent statistician. Par-
ticipants will be randomised to one of three arms as per
Fig. 1. At each centre, the investigators will be blinded
to allocation order and the treatment will be assigned
using sealed envelopes based on order of recruitment.
Outcome assessors and exercise trainers will not be
blinded to the allocated treatment arm.
Interventions
Exercise intervention
The aim of both the aerobic intervention and stretching
and toning exercise intervention groups will be to accrue
3 x 45 min exercise sessions per week over 12 months.
Participants will complete a combination of supervised
instructor led classes and unsupervised home exercise
sessions. Class attendance and adherence to unsuper-
vised home exercise sessions will be recorded for each
participant by the class instructor each week over the
12 month intervention period.
The goal of the aerobic exercise class will be to accu-
mulate at least 45 min of extensive aerobic exercise, pre-
scribed by heart rate (HR) calculated as 180 bpm – age.
Exercise intensity will be monitored during the super-
vised classes using a HR monitor and subjective report-
ing of the exercise intensity using the Borg’s Rating of
Perceived Exertion (RPE) [36]. Participants in the aer-
obic exercise group will aim to achieve a target RPE of
13 while exercising. Each supervised class will be com-
prised of a 5–10 min warm up, 45 min of targeted aer-
obic exercise and a 5–10 min cool down. A range of
aerobic exercise modalities will be offered including cyc-
ling, treadmill walking, elliptical training, endurance re-
lated indoor activities, outdoor walking, jogging and
aqua jogging.
The aim of the stretching and toning group will be to
complete non-aerobic activities. Each supervised class
will be comprised of a 5–10 min warm up, 45 min of
stretching, balance, coordination, relaxation, group
games and light resistance exercises and a 5–10 min
cool down. During the stretching and toning class,
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exercise intensity will not exceed an RPE of 10. Partici-
pants in the stretching and toning group will not be ad-
vised about aerobic activity and will not be instructed to
avoid completing routine aerobic activity. The stretch-
ing and toning group will act as a social control group
and it is not anticipated to see significant improve-
ment in study outcomes.
The control group will receive usual care and will not
be advised about exercise or attend supervised sessions.
Participants in the control group will complete outcome
assessments.
Outcome assessment
All outcomes will be measured at T0 (Baseline), T1
(6 months) and T2 (12 months) time points. Brain MRI,
blood sampling for epigenetic analysis and the NEO-Five
Factor Inventory (NEO-FFI) will only be measured at T0
and T2. All participants will undergo described tests,
except for MRI (only in Cologne and Nijmegen).
Primary outcome
Cognitive function
The primary outcome is cognitive performance. Cogni-
tive performance will be assessed by a neuropsycho-
logical test battery measuring six cognitive domains. The
test battery will consist of a computer based CogState
Battery including the International Shopping List Task
(ISLT) – immediate and delayed recall, Detection Task,
Identification Task, One Back Task and One Card Learn-
ing Task (https://cogstate.com/) [37, 38], Verbal fluency
[39, 40] and Trail Making Test (TMT) [41].
The allocation of to the tests to the six cognitive domains
is based on the CogState Guidelines and conventional clas-
sification of neuropsychological tests [42]. Verbal memory
will be assessed by ISLT. Psychomotor function will be mea-
sured with the Detection Task. Executive function will in-
clude TMT-B, Letter Fluency and Category Fluency.
Attention will be assessed by the Identification Task and
TMT-A. Working memory will be measured by One Back
Task, and Visual memory by the One Card Learning Task.
A description of the tasks is described below.
The CogState battery will take approximately 30 min
to complete. The ISLT is a 12 word, four trial (three
learning trials and one delayed recall trial). Total num-
ber of correct responses made in remembering the list
on three consecutive trials at a single session and after a
delay will be recorded. The ISLT has been shown to have
good sensitivity to verbal memory impairment [43]. The
Detection Task measures psychomotor functioning and
speed of processing. Participants must respond as
quickly as possible when the card shown face down in
the centre of the screen flips over by pressing a button
on the keyboard. Reaction time is measured with lower
scores indicating better performance. The Identification
Task measures visual attention. Participants must decide
whether a playing card presented on screen is red, by
pressing the ‘Yes’ or ‘No’ button. Reaction time is mea-
sured and lower scores indicate better performance. The
One Back Task assesses working memory. Participants
are presented with a sequence of playing cards in the
centre of a screen and must decide if the card presented
is the same as the one shown immediately before. The
One Card Learning Task measures visual learning and
memory. Participants are presented with a succession of
playing card on screen, and must decide if the card cur-
rently displayed has been displayed previously. Accuracy
of performance is measured, with higher scores indicat-
ing better performance. A number of studies have found
that the CogState battery of tests are sensitive to detect-
ing cognitive impairment in mild to moderate AD and
amnestic MCI populations relative to healthy matched
controls [44]. CogState and has been validated across a
broad range of cognitively impaired populations [38].
Verbal fluency will be assessed with Letter Fluency
[39] and Category Fluency [40]. For the Letter Fluency
test participants are allowed one minute to generate as
many words as possible that begin with a specific letter.
This task will be repeated three times with three differ-
ent letters (e.g. F, A, S). For the category fluency test,
participants must give as many examples of animals as
possible within one minute.
TMT will be completed as a paper and pen based task.
The TMT consists of two sub trials. TMT-A require individ-
uals to sequentially connect 25 encircled numbers on a sheet
of paper, while TMT-B require participants to draw a line, al-
ternating between numbers and letters in ascending order.
Secondary outcomes
Secondary outcomes will include global cognitive func-
tion, cardiovascular fitness, physical activity, quality of life,
depression, measures of frailty and epigenetic changes.
MoCA screening tool will be used as a broad measure
of global cognitive function. The MoCA is a one-page
30-point test administered in 10 min which consists of
13 tasks covering the following eight cognitive domains:
visuospatial/executive functions, naming, verbal memory
registration and learning, attention, abstraction, delayed
verbal memory, and orientation. It has demonstrated
high sensitivity and specificity as a cognitive screening
instrument and has been validated to detect MCI [31].
Cardiovascular fitness will be assessed using an incre-
mental exercise test on a standard cycle ergometer. Par-
ticipants at the German Sports University and Trinity
College Dublin will complete a maximal test in accord-
ance with the World Health Organisation Protocol [45].
The test will commence with 3 min cycling unloaded,
followed by the incremental phase of exercise during
which the load will increase by 25 W every two minutes
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until the test is terminated. Blood lactate levels and par-
ticipants reported BORG RPE scores will be measured at
each stage of the test (2 min intervals). At the University
of Nijmegen, aerobic fitness will be estimated from a
submaximal exercise test completed according to the
Astrand-Rhyming submaximal protocol [46]. During the
first two minutes, resistance of the ergometer will be
increased until a steady state HR of 70% of the esti-
mated maximal HR is reached. Participants continue
pedalling for 6 min. HR and RPE will be recorded
every minute. VO2max will be estimated using the aver-
age HR of minute 5 and 6 and the work load in the
Astrand Nomogram.
Physical activity will be assessed objectively using an
activity accelerometer to be worn for seven consecutive
days by study participants as each assessment time point
and subjectively with the LASA Physical Activity Ques-
tionnaire (LAPAQ). The LAPAQ questionnaire is a valid
and reliable self-reported questionnaire that captures
physical activity over the preceding 14 days [47].
Health related quality of life will be evaluated using
the Health Related Quality of Life for People with
Dementia (DemQOL). DemQOL is a 28 item interview
administered questionnaire relating to different aspect of
QOL. The DemQOL has been validated in a large sam-
ple of people with dementia and demonstrates good ac-
ceptability and internal consistency [48]. It has also been
used in older adults and in patients with MCI [49]. In
addition, the Center for Epidemiologic Studies Depression
(CES-D) questionnaire will be administered to determine
depressive symptoms. The CES-D Scale is a short self-
report questionnaire that measures symptomatic depression
[50] that has been validated as a depression screening tool
in older adults [51]. Depressive symptoms are associated
with increased risk of MCI [52]. The association of de-
pression with prevalent MCI and with progression from
MCI to dementia, but not with incident MCI, suggests
that while depression is prevalent in MCI, it does not
precede it [53].
Measures of frailty will include The Timed Up and Go
(TUG) test, hand grip strength and 30 s chair stand. The
TUG will assess the participant’s mobility and balance.
The TUG is a reliable and valid test for quantifying func-
tional mobility and is useful in following clinical change
in frailty over time [54]. Hand grip strength will be mea-
sured using a Jamer Digital Dynamometer as a measure
of upper limb strength. A standardised approach will be
taken to obtaining the measurement [55]. Hand‐Grip
strength has been shown to predict future outcomes in
aging adults including mortality and future levels of dis-
ability [56]. The 30 s chair stand will determine lower
limb strength and endurance. Lower body strength is
considered critical in evaluating the functional perform-
ance of older adults [57].
Venous blood samples will be collected for genetic and
epigenetics analysis performed on a Sequenom Massarray
Analyzer 4 at the Department of Psychology University of
Bonn, Germany. Genotyping of the Apolipoprotein E
(APOE) and the Brain Derived Neurotrophic Factor
(BDNF) genes and their epigenetic methylation patterns
will be the primary focus. The genetic analyses will serve
as predisposed risk and resilience factors for cognitive
functioning and decline in MCI participants. The epi-
genetic findings will shed new light on the link between
exercise and gene activation of relevant genes in the
biochemical pathways underlying cognitive decline.
Given the moderating effect of the common genetic
variation of APOE via personality on AD onset [58], the
NEO-Five Factor Inventory (NEO-FFI) will be included
to assess personality traits such as neuroticism or extra-
version, predicting an earlier onset of Alzheimer and
cognitive decline in elderly humans [59]. NEO-FFI is a
psychological personality inventory consisting of 60
items to measure five personality traits. The question-
naire will be completed following each blood draw to
form part of the epigenetics analysis. The NEO-FFI is
also discussed as a measure of emotional intelligence
[60].
Structure and function of related brain regions will
be measured using functional MRI (fMRI) brain which
is a non-invasive method for examining brain activity
and structure. Structural imaging will include isotropic
T1-weighted-, T2-weighted- and FLAIR- sequences
with an isotropic spatial resolution of 1x1x1mm. The
combination of the different image weightings allows
for an automatic detection/volumetry of white matter
lesions. Additionally, the combination of these se-
quences improves image segmentation. The structural
protocol will be rounded up by a 3D-DTI sequence (60
diffusion directions, 1.7x1.7x1.7 mm) and a resting
state fMRI Table 1.
Safety
All serious adverse events (SAE)/adverse events (AE) will
be recorded on study specific adverse event forms. All
AE’s will be registered with the local principle investiga-
tor (PI). These will be discussed at regular team meet-
ings and collected and registered at the end of the study.
All SAE’s will be registered centrally. In the case of an
SAE, all site PI’s will be informed both at time of occur-
rence (with 24 h) and for a final conclusion on causality.
Sample size
The sample size estimation was performed in “G*Power”, a
statistical software program. The effect size was estimated,
based on the effect size found in several studies examining
the effect of exercise on cognition in elderly with MCI or
increased risk for AD [8–10, 61, 62]. Sample size was
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calculated based on a two-tail statistical t-test set 1-β =
0.80, α = 0.05, an effect size of 0.4, an allocation ratio N2/
N1 of 2. A total sample size of 224 was calculated. Consid-
ering a correlation of 0.5 between the outcome measures
at T0 and T2, the design design-factor D = 1-0.52 = 0.75.
The expected dropout rate is 25%. 224*0.75*1.25 = 210.
Considering the fact that the primary analysis will be a
combination of the results of three different centres, the
final sample size n = 210 is rounded up to n = 225.
Statistical analysis
The primary analysis of this study will be comparison of
cognitive functioning (primary outcome measure) be-
tween all three intervention arms before (T0) and after
(T2) the 1 year intervention. A composite score will be
calculated by averaging all six domain scores into one
overall cognition score. The obtained scores per test will
be converted into z-scores based on the standard devi-
ation and mean of the total sample at baseline. In case
of multiple tests within one domain, the average z-score
for the domain will be calculated. Secondary outcome
measures are the six separate cognitive domain scores
and the other parameters.
For the primary analysis we will have an intervention
group of n = 150 (both exercise forms together) and a
control group of n = 75 as input of an ANCOVA with
dependent variable the change in cognitive composite
score between T2 and T0, and as covariates baseline
cognitive functioning, sex, age. In a secondary analysis
the comparison between the two exercise forms will be
carried out in a similar ANCOVA analysis.
Analyses for all secondary outcome parameters will be
carried out with similar ANCOVA analyses. Secondary
analyses will also elucidate the contrasts between T0 and
T1 and T2 for the primary and secondary outcomes, and
thus elucidate the course over time, without correction for
multiple comparisons, as these analyses are exploratory.
Furthermore, to assess change in physical fitness, qual-
ity of life, cerebral structure and epigenetics a similar
statistical approach will be used as for the primary study
parameter. A p-value of < 0.05 will be used to assess stat-
istical significance.
Data management
All data will be managed using unique study codes to
protect participant confidentiality, which will be used to
code and file all electronic information. The key linking
this code to participant identity will be stored in a secured
file, access to this key is available only to designated
members of the research team at each site. Raw data
Table 1 SPIRIT diagram outlining schedule of enrolment, interventions, and assessments for study participants
Timepoints Pre-screening
telephone call
Baseline assessment T0 Study assessment T1 Study assessment T2
<13 days following
screening
6 months after study
visit 1
12 months after study
visit 1
Enrolment Explain study X
Screen eligibility criteria X
Study Outcomes Neuropsychological testing X X X
MoCA X X X
DemQOL X X X
CES-D X X X
Incremental Exercise Test X X X
Physical Activity Tracker X X X
LAPAQ X X X
Blood sampling X X
NEO-FFI X X
MRI Braina X X
TUG X X X
Hand Grip Strength X X X
30 second chair stand X X X
Randomisation (after completion
of all baseline assessments)
X
Exercise interventionb X X X
aMRI brain will be performed in Cologne and Nijmegen sites
bAfter completion of T0 assessment, participants will be randomised to one of the three groups (aerobic exercise, stretching and toning exercise, control group).
Exercise intervention will be continuous for a 12-month duration following completion of T0 assessments
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will be stored in a file cabinet with a lock where only desig-
nated research team members will have access to the key.
Discussion
To the best of our knowledge, there have been no inter-
vention trials evaluating the effect of an extensive, con-
trolled and structured 12-month exercise programme on
the progression of cognitive decline in an MCI popula-
tion. Since the neuropathological change process can
take years after onset of MCI, the addition of longer
intervention period may result in larger intervention effects.
An important consideration of this study is the isolated aer-
obic exercise intervention. A number of exercise interven-
tion studies have implemented multimodal exercise
interventions [11, 63], making it difficult to interpret the ef-
fect of isolated exercise modalities. The large sample size,
longer duration of exercise intervention, comprehensive
neuropsychological test battery will enhance the existing re-
search around exercise and cognitive function in MCI.
The secondary outcomes will examine several potential
underlying mechanisms that may influence the exercise-
cognitive relationship in MCI. The effect of exercise on
brain structure and function measured by MRI brain will
be examined. Methylation analyses of the APOE gene and
neurotrophic genes will explore the effects of exercise on
this known AD risk factor. Static gene polymorphisms will
be used to predict intervention outcomes. Finally, cardio-
vascular fitness will be measured and examined as a
moderator of the exercise-cognitive relationship in MCI.
While cognitive performance is the primary outcome, we
will also assess whether participation in a structured exer-
cise programme or changes in cognition can influence
quality of life and measures of frailty, known risk factors
for cognitive further decline [64].
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controlled trial; RPE: Rate of perceived exertion; SAE: Serious adverse event;
SD: Standard deviation; TMT: Trail making test; TUG: Timed up and go;
WMS: Wechsler memory scale
Acknowledgments
Members of the NeuroExercise Study Group (in alphabetical order by name).
Dr. Justine A. Aaronson, Department of Medical Psychology, Radboud
University Medical Center, Nijmegen, The Netherlands; Dr. Vera Abeln,
Institute of Movement and Neurosciences, German Sport University Cologne,
Germany; Dr. Jurgen A.H.R Claassen, Department of Geriatric Medicine,
Radboud University Medical Center, Donders Institute for Brain, Cognition
and Behaviour, Nijmegen, The Netherlands; Dr. Robert F. Coen, Mercer’s
Institute for Research on Ageing, St. James’s Hospital, Dublin, Ireland; Dr.
Emer M. Guinan, School of Medicine, Trinity College Dublin, Ireland; Dr.
Damien Ferguson, Department of Neurology, St. James’s Hospital, Dublin,
Ireland; Prof. Roy P.C. Kessels, Department of Medical Psychology, Radboud
University Medical Center, Donders Institute for Brain, Cognition and
Behaviour, Nijmegen, The Netherlands; Prof. Romain Meeusen, Human
Physiology Research Group, Vrije Universiteit Brussels, Belgium; Prof. Christian
Montag, Institute of Psychology and Education, Ulm University, Germany and
Key Laboratory for NeuroInformation/Center for Information in Medicine, and
School of Life Science and Technology, University of Electronic Science and
Technology of China, Chengdu, China; Dr Ross T. Murphy, St. James’s
Hospital, Dublin, Ireland; Prof. M. Cristina Polidori, Ageing Clinical Research,
University Hospital of Cologne, Germany; Prof. Martin Reuter, University of
Bonn, Department of Psychology and Center for Economics & Neuroscience,
Laboratory of Neurogenetics, Bonn, Germany; Prof. Heiko K. Strüder, Institute
of Movement and Neurosciences, German Sport University Cologne,
Germany; Tim Stuckenschneider, Institute of Movement and Neurosciences,
German Sport University Cologne, Germany; Prof H.J. Thijssen, Department of
Physiology, Radboud University Medical Center, Nijmegen, The Netherlands;
Prof. Tobias Vogt, Institute for Professional Sport Education and Sport
Qualifications, German Sport University Cologne, Germany; Prof. Cathal
Walsh, University of Limerick, Ireland; Prof. Bernd Weber, Department of
Epileptology, University Hospital Bonn, Germany.
We would like to acknowledge the following network of hospital sites and
investigators who have assisted in recruiting participants to this study at the
Dublin site; Dr Jennifer Hoblyn, Bloomfield Healthcare; Dr Andrew Eustace,
Highfield Healthcare; Dr Cora McGreevy, Mater Misericordiae University
Hospital; Dr Aisling Denihan, Old Age Psychiatry Navan; Dr Justin Kinsella, St.
Vincent’s University Hospital; Dr Declan Lyons, St. Patrick’s University Hospital
and Dr Sean Kennelly, Tallaght Hospital.
Funding
The project has been supported by The EU Joint Programme –
Neurodegenerative Disease Research (JPND). JPND did not contribute to
the study design or in writing the manuscript. German grant number BMBF
01ED1510A. Health Research Board Ireland grant number JPND-2014-1. Dutch
grant number: ZonMw 733051044.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or
analysed during the current study.
Authors’ contributions
SS, BL and MOR developed the idea for the study. KD, EG and MS drafted
the protocol with input from all authors on study design and revisions to
the protocol paper. All authors have approved the final version of this paper
prior to submission.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study protocol is approved by the Tallaght Hospital/St. James's Hospital
Joint Research Ethics Committee Dublin Ireland (reference 2015/09/04; 14/
12/2015), the German Sport University, Cologne Germany (reference 9/2015;
21/01/15) by Commissie Mensgebonden Onderzoek Arnhem-Nijmegen,
Netherlands (reference 2015-1872).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland. 2Trinity
College Institute of Neuroscience, Dublin, Ireland. 3Department of Geriatric
Medicine, Radboud Alzheimer Centre, Radboud University Medical Center,
Nijmegen, The Netherlands. 4Institute of Movement and Neurosciences,
German Sport University Cologne, Cologne, Germany. 5Faculty for Science,
Health, Education and Engineering, University of the Sunshine Coast,
Maroochydore, Australia.
Devenney et al. BMC Geriatrics  (2017) 17:75 Page 8 of 10
Received: 29 September 2016 Accepted: 3 March 2017
References
1. Wimo A, Jönsson L, Gustavsson A, McDaid D, Ersek K, Georges J, Gulacsi L,
Karpati K, Kenigsberg P, Valtonen H. The economic impact of dementia in
Europe in 2008—cost estimates from the Eurocode project. Int J Geriatr
Psychiatry. 2011;26:825–32.
2. Kirton J. A summit of significant success: prospects for the G8 leaders at
lough erne. G8 Res Group. 2013;12:2013.
3. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A,
Holtzman DM, Jagust WJ, Petersen RC. The diagnosis of mild cognitive
impairment due to Alzheimer’s disease: Recommendations from the
National Institute on Aging-Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–9.
4. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-
Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D. Revising the definition
of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118–27.
5. Pieramico V, Esposito R, Cesinaro S, Frazzini V, Sensi SL. Effects of non-
pharmacological or pharmacological interventions on cognition and brain
plasticity of aging individuals. Front Syst Neurosc. 2014;8:153.
6. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R,
Bäckman L, Hänninen T, Jula A, Laatikainen T. A 2 year multidomain
intervention of diet, exercise, cognitive training, and vascular risk
monitoring versus control to prevent cognitive decline in at-risk elderly
people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255–63.
7. Geda YE, Roberts RO, Knopman DS, Christianson TJ, Pankratz VS, Ivnik RJ,
Boeve BF, Tangalos EG, Petersen RC, Rocca WA. Physical exercise, aging,
and mild cognitive impairment: a population-based study. Arch Neurol.
2010;67:80–6.
8. Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on
elderly persons with cognitive impairment and dementia: a meta-analysis.
Arch Phys Med Rehabil. 2004;85:1694–704.
9. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A,
Plymate SR, Fishel MA, Watson GS, Cholerton BA. Effects of aerobic exercise
on mild cognitive impairment: a controlled trial. Arch Neurol. 2010;67:71–9.
10. Nagamatsu LS, Chan A, Davis JC, Beattie BL, Graf P, Voss MW, Sharma D, Liu-
Ambrose T. Physical activity improves verbal and spatial memory in older
adults with probable mild cognitive impairment: a 6-month randomized
controlled trial. J Aging Res. 2013;2013:861893. doi:10.1155/2013/861893.
11. Nascimento CMC, Pereira JR, Pires de Andrade L, Garuffi M, Ayan C, Kerr DS,
Talib LL, Cominetti MR, Stella F. Physical exercise improves peripheral BDNF
levels and cognitive functions in mild cognitive impairment elderly with
different bdnf Val66Met genotypes. J Alzheimer Dis. 2015;43:81–91.
12. Zheng G, Xia R, Zhou W, Tao J, Chen L. Aerobic exercise ameliorates cognitive
function in older adults with mild cognitive impairment: a systematic review
and meta-analysis of randomised controlled trials. Br J Sports Med. 2016;50:
1443–50.
13. Gates N, Singh MAF, Sachdev PS, Valenzuela M. The effect of exercise training
on cognitive function in older adults with mild cognitive impairment: a meta-
analysis of randomized controlled trials. Am J Geriatr Psychiatry. 2013;21:1086–97.
14. Kirk-Sanchez NJ, McGough EL. Physical exercise and cognitive performance
in the elderly: current perspectives. Clin Interv Aging. 2014;9:51–62.
15. Boecker H, Sprenger T, Spilker ME, Henriksen G, Koppenhoefer M, Wagner
KJ, Valet M, Berthele A, Tolle TR. The runner’s high: opioidergic mechanisms
in the human brain. Cereb Cortex. 2008;18:2523–31.
16. Vogt T, Schneider S, Abeln V, Anneken V, Strüder HK. Exercise, mood and
cognitive performance in intellectual disability—A neurophysiological
approach. Behav Brain Res. 2012;226:473–80.
17. Chaddock L, Hillman CH, Pontifex MB, Johnson CR, Raine LB, Kramer AF.
Childhood aerobic fitness predicts cognitive performance one year later.
J Sports Sci. 2012;30:421–30.
18. Vaynman S, Gomez‐Pinilla F. Revenge of the “sit”: how lifestyle impacts
neuronal and cognitive health through molecular systems that interface
energy metabolism with neuronal plasticity. J Neurosci Res. 2006;84:699–715.
19. Gomez‐Pinilla F, Hillman C. The influence of exercise on cognitive abilities.
Compr Physiol. 2013;3:403–28.
20. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo
S, Alves H, White SM. Exercise training increases size of hippocampus and
improves memory. Proc Natl Acad Sci. 2011;108:3017–22.
21. Holzschneider K, Wolbers T, Röder B, Hötting K. Cardiovascular fitness modulates
brain activation associated with spatial learning. Neuroimage. 2012;59:3003–14.
22. Budde H, Brunelli A, Machado S, Velasques B, Ribeiro P, Arias-Carrión O,
Voelcker-Rehage C. Intermittent maximal exercise improves attentional
performance only in physically active students. Arch Med Res. 2012;43:125–31.
23. Voss MW, Chaddock L, Kim JS, VanPatter M, Pontifex MB, Raine LB, Cohen
NJ, Hillman CH, Kramer AF. Aerobic fitness is associated with greater
efficiency of the network underlying cognitive control in preadolescent
children. Neuroscience. 2011;199:166–76.
24. Gómez-Pinilla F, Feng C. Molecular mechanisms for the ability of exercise
supporting cognitive abilities and counteracting neurological disorders. In
Functional Neuroimaging in Exercise and Sport Sciences. New York:
Springer; 2012:25–43.
25. Wang Z, van Praag H. Exercise and the brain: neurogenesis, synaptic plasticity,
spine density, and angiogenesis. In Functional Neuroimaging in Exercise and
Sport Sciences. New York: Springer; 2012:3–24.
26. Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases
amyloid load in a transgenic model of Alzheimer's disease. J Neurosci.
2005;25:4217–21.
27. Ke H-C, Huang H-J, Liang K-C, Hsieh-Li HM. Selective improvement of cognitive
function in adult and aged APP/PS1 transgenic mice by continuous non-shock
treadmill exercise. Brain Res. 2011;1403:1–11.
28. Unger JB, Johnson CA, Marks G. Functional decline in the elderly: evidence
for direct and stress-buffering protective effects of social interactions and
physical activity. Ann Behav Med. 1997;19:152–60.
29. Lam LC, Chau R, Wong BM, Fung AW, Lui VW, Tam CC, Leung GT, Kwok TC,
Chiu HF, Ng S. Interim follow‐up of a randomized controlled trial comparing
Chinese style mind body (Tai Chi) and stretching exercises on cognitive
function in subjects at risk of progressive cognitive decline. Int J Geriatr
Psychiatry. 2011;26:733–40.
30. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med.
2004;256:183–94.
31. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I,
Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief
screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.
32. Wechsler D. Wechsler adult intelligence scale-fourth. San Antonio, TX: The
Psychological Corporation Google Scholar; 2008.
33. Hendriks M, Bouman Z, Kessels R, Aldenkamp A. Wechsler Memory Scale-
Dutch Edition (WMS-IV-NL). Amsterdam: Pearson Assessment; 2014.
34. Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the
assessment of neuropsychological Status (RBANS): preliminary clinical validity.
J Clin Exp Neuropsychol. 1998;20:310–9.
35. Corrado D, Pelliccia A, Heidbuchel H, Sharma S, Link M, Basso C, Biffi A,
Buja G, Delise P, Gussac I. Recommendations for interpretation of 12-lead
electrocardiogram in the athlete. Eur Heart J. 2010;31:243–59.
36. Borg G. Borg’s perceived exertion and pain scales. Champaign: Human
Kinetics; 1998.
37. de Jager CA, Schrijnemaekers A-CM, Honey TE, Budge MM. Detection of
MCI in the clinic: evaluation of the sensitivity and specificity of a computerised
test battery, the Hopkins Verbal Learning Test and the MMSE. Age Ageing.
2009;38(4):455–60. doi:10.1093/ageing/afp068.
38. Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, Pietrzak RH. Validity
of the CogState brief battery: relationship to standardized tests and sensitivity
to cognitive impairment in mild traumatic brain injury, schizophrenia, and
AIDS dementia complex. Arch Clin Neuropsychol. 2009;24:165–78.
39. Thurstone LL. Primary mental abilities. In The Measurement of Intelligence.
Netherlands: Springer; 1973:131–136.
40. Benton A, Hamsher K, Sivan A. Multilingual Aphasia Examination. Iowa City,
IA: AJA Associates. Inc; 1989.
41. Reitan RM. The relation of the trail making test to organic brain damage.
J Consult Psychol. 1955;19:393.
42. Lezak MD. Neuropsychological assessment. USA: Oxford University Press; 2004.
43. Thompson TA, Wilson PH, Snyder PJ, Pietrzak RH, Darby D, Maruff P, Buschke H.
Sensitivity and test–retest reliability of the international shopping list test in
assessing verbal learning and memory in mild Alzheimer's disease. Arch Clin
Neuropsychol. 2011;26:412–24.
44. Lim YY, Ellis KA, Harrington K, Ames D, Martins RN, Masters CL, Rowe C,
Savage G, Szoeke C, Darby D. Use of the CogState Brief Battery in the
assessment of Alzheimer's disease related cognitive impairment in the
Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp
Neuropsychol. 2012;34:345–58.
Devenney et al. BMC Geriatrics  (2017) 17:75 Page 9 of 10
45. Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, Froelicher
VF, Leon AS, Piña IL, Rodney R. Exercise standards for testing and training a
statement for healthcare professionals from the American Heart Association.
Circulation. 2001;104:1694–740.
46. Åstrand P-O, Ryhming I. A nomogram for calculation of aerobic capacity
(physical fitness) from pulse rate during submaximal work. J Appl Physiol.
1954;7:218–21.
47. Stel VS, Smit JH, Pluijm SM, Visser M, Deeg DJ, Lips P. Comparison of the
LASA Physical Activity Questionnaire with a 7-day diary and pedometer.
J Clin Epidemiol. 2004;57:252–8.
48. Smith S, Lamping D, Banerjee S, Harwood R, Foley B, Smith P, Cook J, Murray J,
Prince M, Levin E. Measurement of health-related quality of life for people with
dementia: development of a new instrument (DEMQOL) and an evaluation of
current methodology. Health Technol Assess. 2005;9:1–93.
49. Mhaoláin AMN, Gallagher D, Crosby L, Ryan D, Lacey L, Coen RF, Coakley D,
Walsh JB, Cunningham C, Lawlor B. Frailty and quality of life for people with
Alzheimer’s dementia and mild cognitive impairment. Am J Alzheimers Dis
Other Demen. 2012;27:48–54.
50. Radloff LS. The CES-D scale a self-report depression scale for research in the
general population. Appl Psychol Meas. 1977;1:385–401.
51. Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult:
criterion validity of the 10-item Center for Epidemiological Studies Depression
Scale (CES-D). Arch Intern Med. 1999;159:1701–4.
52. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive
symptoms, vascular disease, and mild cognitive impairment: findings from
the Cardiovascular Health Study. Arch Gen Psychiatry. 2006;63:273–9.
53. Richard E, Reitz C, Honig LH, Schupf N, Tang MX, Manly JJ, Mayeux R,
Devanand D, Luchsinger JA. Late-life depression, mild cognitive impairment,
and dementia. JAMA Neurol. 2013;70:383–9.
54. Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional
mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–8.
55. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A
review of the measurement of grip strength in clinical and epidemiological
studies: towards a standardised approach. Age Ageing. 2011;40(4):423–9.
doi:10.1093/ageing/afr051.
56. Bohannon RW. Hand‐grip dynamometry predicts future outcomes in aging
adults. J Geriatr Phys Ther. 2008;31:3–10.
57. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower
body strength in community-residing older adults. Res Q Exerc Sport.
1999;70:113–9.
58. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske
A, Pedersen NL. Role of genes and environments for explaining Alzheimer
disease. Arch Gen Psychiatry. 2006;63:168–74.
59. Montag C, Kunz L, Axmacher N, Sariyska R, Lachmann B, Reuter M. Common
genetic variation of the APOE gene and personality. BMC Neurosci. 2014;15:1.
60. Schutte NS, Malouff JM, Hall LE, Haggerty DJ, Cooper JT, Golden CJ,
Dornheim L. Development and validation of a measure of emotional
intelligence. Personal Individ Differ. 1998;25:167–77.
61. Sofi F, Valecchi D, Bacci D, Abbate R, Gensini GF, Casini A, Macchi C. Physical
activity and risk of cognitive decline: a meta‐analysis of prospective studies.
J Intern Med. 2011;269:107–17.
62. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J,
Greenop KR, Almeida OP. Effect of physical activity on cognitive function in
older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;
300:1027–37.
63. Suzuki T, Shimada H, Makizako H, Doi T, Yoshida D, Tsutsumimoto K, Anan
Y, Uemura K, Lee S, Park H. Effects of multicomponent exercise on cognitive
function in older adults with amnestic mild cognitive impairment: a randomized
controlled trial. BMC Neurol. 2012;12:1.
64. Robertson DA, Savva GM, Kenny RA. Frailty and cognitive impairment—a
review of the evidence and causal mechanisms. Ageing Res Rev. 2013;
12:840–51.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Devenney et al. BMC Geriatrics  (2017) 17:75 Page 10 of 10
